Revisit Every OncLive On Air Episode From June 2026

In case you missed any, below is a recap of the episodes of OncLive On Air® that aired in June 2026. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD

In this episode of Precision and Progress: Radiotherapy in Oncology, hosts Hirsch Matani, MD, and Elizabeth Zhang-Velten, MD, PhD, sat down with Binh T. Ngo, MD, all of the Keck School of Medicine of the University of Southern California in Los Angeles, to discuss the evolving roles of systemic therapy, radiation, and multidisciplinary collaboration for patients with melanoma and other skin cancers.

“The radiation for skin cancers is fairly good,” Matani stated. “It has improved in terms of us being able to target and treat these difficult regions with minimal toxicity depending upon the location. We have a number of different treatment regimens we can use, ranging from approximately 2 weeks up to approximately 5 weeks.”

“I will go as long as 6 weeks of radiation, Monday through Friday, if I’m worried about healing,” Zheng said. “Let’s say [a patient] has poor vasculature [or] a known history of peripheral vascular disease. I may even go low and slow to 6 weeks to hopefully reduce the chance of a chronic wound.”

“We made a lot of progress in terms of our treatment of patients with advanced melanoma, because I remember prior to the advent of immunotherapy in 2011 with ipilimumab [Yervoy], patients, when they got the diagnosis of advanced melanoma, were just waiting to die,” Ngo added.

ASCO 2026 Plenary: RASolute 302

In this episode of Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis and Karine Tawagi, MD, of the University of Illinois in Chicago, highlight landmark findings from the phase 3 RASolute 302 trial (NCT06625320) that were presented at the 2026 ASCO Annual Meeting and support the second-line use of daraxonrasib (RMC-6236) for the treatment of patients with metastatic pancreatic adenocarcinoma.

“The median OS for the RAS G12-mutated population was 13.2 months with daraxonrasib compared with 6.6 months [with chemotherapy],” Armstrong explained. “The HR was 0.40 for that population. This is what got the standing ovation, because there was a 60% reduction of risk of death. This is unprecedented in second-line metastatic pancreatic adenocarcinoma.”

“With breakthrough therapy designation and accelerated review underway, full approval [for daraxonrasib] is hopefully on the horizon,” according to Tawagi. “Think about referring your patients with pancreatic cancer for eligible trials.”

Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD

In this video episode of OncLive On Air, Joshua Richter, MD, of Mount Sinai in New York, New York, previewed some of the most-anticipated data from the 2026 EHA Congress.

“Some of the biggest themes [in multiple myeloma at EHA 2026] are immunotherapy and how can we optimize that for patients, both in terms of, at one point in time, giving a bispecific plus additional drugs, and how we want to position CAR T-cell therapy and any maintenance therapy after that,” Richter stated. “How are we best suited to mix and match some of these targets that we know work amazing as monotherapies? Can we use them all together?”

How Curiosity and Empathy Build a Life of Meaningful Accomplishments and Deep Connections: With Erin Schenk, MD, PhD; and D. Ross Camidge, MD, PhD

In this episode of How This Is Building Me, guest host Erin Schenk, MD, PhD, of the University of Colorado Anschutz in Aurora, interviewed D. Ross Camidge, MD, PhD, about his wide-ranging career as a medical oncologist and beyond, as well as how his experiences both caring for patients and being a patient himself have helped shape his perspective.

“[Since] I went public with my diagnosis, people have been incredibly nice to me,” Camidge shared. “The first thing is—it’s probably even worse if you’re British—you sort of brush it off. The first step was I had to learn how to say thank you. I had to learn how to accept a compliment, at least verbally. But the biggest thing was learning how to actually absorb it, to actually say, this is somebody giving, you know, interests, love, support.”

“Your powerful introduction of who you are and where you’ve learned how to accept love, that’s a profound statement,” Schenk summarized.

ADCs, and Metabolic Health Strategies, and Lifestyle Interventions Add up to Holistic TNBC Care: With Chandler Park, MD; and Neil M. Iyengar, MD

In this video episode of Oncology Unplugged, host Chandler Park, MD, of Norton Cancer Institute in Louisville, Kentucky, sat down with Neil M. Iyengar, MD, of the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss updates in the triple-negative breast cancer treatment paradigm, ranging from the introduction of novel antibody-drug conjugates (ADCs) to best practices for toxicity management.

“I consider the appropriate patient for datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) to be somebody who is engaged with their care and who’s proactive, because prophylaxis is important,” Iyengar emphasized. “Generally speaking, I find that Dato-DXd is a well-tolerated regimen, but we need to make sure patients are keeping up on mucositis prophylaxis.”

“The phase 3 ASCENT-03 trial [(NCT05382299) regimen] is also a strong treatment regimen with sacituzumab govitecan-hziy [Trodelvy] for when you start thinking about patients with mucositis [or] a predisposed eye condition vs diarrhea vs neutropenia,” Park added.

Oral SERDs Transform Metastatic Breast Cancer Management: With Sara Nunnery, MD, MSCI; and Vandana G. Abramson, MD

In this video episode of Breast Cancer Briefing, host Sara Nunnery, MD, MSCI, of Tennessee Oncology in Nashville, welcomed Vandana G. Abramson, MD, of the Vanderbilt-Ingram Cancer Center in Nashville, to highlight the ever-evolving role of oral selective estrogen receptor degraders in the treatment of patients with hormone receptor–positive breast cancer.

“You can’t just directly compare trials next to each other, because there are so many nuances that go into what the results might be,” Nunnery explained. “You can be misled easily if you’re immediately latching onto a result and not thinking about all the other factors at play that might underlie why the results are what they are.”

“One of the greatest biomarkers is how long [patients] were on their first line of endocrine therapy,” Abramson noted. “Those who were on for 1, 2, or 3 years are the ones where the estrogen receptor is driving the [tumor] growth.”

As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

In this episodeof OncLive On Air, Brad Haverkos, MD, of the University of Colorado, gave a comprehensive overview of the cutaneous T-cell lymphoma treatment paradigm, from early-stage to advanced disease, and suggested strategies for managing treatment-related toxicities.

“Some studies suggest that patients who have a rash [with mogamulizumab-kpkc (Poteligeo) treatment] are the ones [who] respond better,” He said. “We try not to make [rashes] a dose-limiting toxicity, and if there’s a way to treat through them, we try to do that.”

KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

In this episode of OncLive On Air, Zev A. Wainberg, MD, of the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, spotlighted the range of roles for KRAS-directed therapy in pancreatic ductal adenocarcinoma management.

“It’s been a long pursuit to get to where we are today,” Wainberg shared. “Credit [goes to] the patients and their families who’ve contributed over the years, and these companies and biological chemists [who] pursued this target with determination. It’s good to see it on the clinical side.”

Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD

In this video episode of OncLive On Air, Noa Biran, MD, of Hackensack Meridian Health and John Theurer Cancer Center in New Jersey, shared insights on the top data in multiple myeloma that were presented at ASCO 2026.

“Access is a very important issue because the majority of the patients with myeloma in this country do not have access to an academic center,” Biran contextualized. “Those are the patients who are maybe not as well informed and are being treated by physicians who may only see 1, 2, or 3 patients with myeloma a year. The most important thing is getting to those patients and those physicians who may not be aware of the T-cell engagers, CAR T-cell therapy, and ADCs. [We need to tell those people] how to manage toxicities with these therapies and make [these treatments] more accessible to patients in the community.”

How Strategic Focus Translates to Forward Momentum Across Cancer Immunology Frontiers: With D. Ross Camidge, MD, PhD; and Nora L. Disis, MD

In this episode of How This Is Building Me, Camidge was joined by Mary (Nora) L. Disis, MD, of the Fred Hutchinson Cancer Center in Seattle, Washington, who shared how her lifelong interest in science led her to pursue a vast career in cancer immunology.

"Finance, focus, fortitude, and fearlessness [are needed] to be able to keep on that cancer vaccine pathway,” Disis described. “But if we do, the rewards are the greatest rewards of mankind. We’ve seen that with infectious diseases. Let’s keep on the cancer vaccine path. We can overcome the hurdles if we can control the buzz.”

“Underneath that warm, fluffy exterior, there is something made of steel where you had to explain to people that you were not going to be their clinical workhorse and that you need to be successful in the lab,” Camidge said of Disis’ determination.

Quadruplet Regimens and T-Cell Redirection Are on the Map of Myeloma Management Strategies: With Chandler Park, MD; Muhamed Baljevic, MD, FACP

In this video episode of Oncology Unplugged, Park welcomed Muhamed Baljevic, MD, FACP, of the Vanderbilt-Ingram Medical Center, who shared insights on the effects of quadruplet regimens, bispecific antibodies, and CAR T-cell therapies on multiple myeloma management.

“I expect that 5 or 7 years from now, we’ll be more focused,” Baljevic stated. “We’re still in the midst of the development of these T-cell redirecting therapies and, their incorporation as early as possible [in the treatment paradigm]. But 5 or 7 years from now, we’ll be looking at the situation where we have the availability of incredibly powerful regimens, incredibly effective regimens, regimens that are going to prolong the progression-free survival to lengths we’ve never seen before.”

“One of the transformative things in myeloma is the cellular therapy, where CAR T-cell therapy is much more mature,” Park added. “Then we have the BCMA target with CAR T-cell therapy and the bispecific antibodies.”

FDA Approval Insights: Decitabine/Cedazuridine Plus Venetoclax for AML: With Courtney D. DiNardo, MD, MSCE

In this episode of OncLive On Air, Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center in Houston, highlighted the significance of the FDA approval of decitabine (Dacogen) and cedazuridine (Inqovi) plus venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia.

“What is impactful about this [approval] is that we now have an all oral [option for patients],” she noted.

Unlocking the Power of ctDNA for Residual Disease, Resistance Monitoring, and Real-Time Treatment Decisions in GI Cancers: With Christopher Lieu, MD

In this video episode of OncLive On Air, Christopher Lieu, MD, of the University of Colorado Anshutz Cancer Center, noted how circulating tumor DNA (ctDNA) testing in gastrointestinal cancer detection and monitoring can lead to treatment decisions, as well as how community oncologists can begin to integrate this practice into their workflows.

“If we have a clinical trial and a drug that can clear ctDNA in a patient who has persistent ctDNA positivity, that is going to be an exciting breakthrough,” Lieu noted. “Can we de-escalate [therapy in patients] with ctDNA negativity? Can we escalate treatment with something better than chemotherapy for the patients who we know are going to recur at an extraordinarily high rate because they’re persistently ctDNA positive?”

Sequencing and Emerging Targets Revamp the Platinum-Resistant Ovarian Cancer Treatment Paradigm: With David O’Malley, MD

In this episode of OncLive On Air, David O’Malley, MD, of The Ohio State University Comprehensive Cancer Center–James in Columbus, explained the nuances of treatment selection and sequencing for patients with platinum-resistant ovarian cancer, including how he integrates ADCs, immunotherapy, and combination regimens.

“It is an ADC world, but we’re not even close to where we’re going to be,” he emphasized.

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

In this video episode of OncLive On Air, Martin Schoen, MD, of Saint Louis University, and Andrew W. Hahn, MD, of The University of Texas MD Anderson Cancer Center, talked through all things androgen receptor pathway inhibitors in metastatic castration-sensitive prostate cancer management.

“Precision [medicine] does not need to be [based on] an RNA signature or a DNA abnormality,” according to Schoen. “Precision [medicine] can be the right drug for the right patient in the right scenario. We have previously not had the best tools or methods, but as our data develop and as things move into real time, I share your excitement for that period of the future where we can hopefully provide even better care for our patients.”

“[Approximately one-quarter] patients with metastatic prostate cancer will die of cardiovascular disease despite having metastatic prostate cancer,” Hahn added. “We can do things to improve that. We have the tools available to us. My cardio-oncologist at The University of Texas MD Anderson Cancer Center will always tell me that things are getting better.”

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

In this video episode of Breast Cancer Briefing, Nunnery sat down with Megan Kruse, MD, of Cleveland Clinic in Ohio, to walk through the design and potential implications of findings from the phase 3 SERENA-6 trial (NCT04964934) investigating a camizestrant switch strategy after ESR1 mutation detection in ctDNA prior to radiographic progression in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

“I worry: Are we delaying [giving] an option that could be meaningful for some patients, or are we delaying getting that to them by waiting years for overall survival?” Nunnery noted.

“There is nothing worse for quality of life than progressing cancer, physically, emotionally, and psychologically,” Kruse explained. “If you think about the tools at our disposal, scans are pretty rudimentary. We’re not using a lot of minimal disease detection tests, partially because we don’t know that that influences overall outcomes.”

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

In this episode of OncLive On Air, Claire Harrison, MD, of Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, noted anemia management strategies for patients with myelofibrosis, as well as key points from the phase 3 INDEPENDENCE trial (NCT04717414) of luspatercept-aamt (Reblozyl) in patients with myelofibrosis-associated anemia.

“The [INDEPENDENCE] data suggest that luspatercept can give a benefit to these patients [with myelofibrosis-associated anemia], but there is still a way to go,” she reported.

FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD

In this episode of OncLive On Air, Charles E. Geyer, MD, of the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania, spotlighted the significance of the FDA approval of neoadjuvant fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for HER2-positive stage II or III breast cancer, as determined by an FDA-authorized test, followed by a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta; THP), as well as the simultaneous approval of post-neoadjuvant T-DXd for HER2-positive breast cancer with residual invasive disease following neoadjuvant HER2-targeted treatment.

“[The approval of T-DXd followed by THP] is an important approval that is going to change the way we [manage] HER2-positive breast cancer here in the US,” he emphasized. He also noted that in the pivotal post-neoadjuvant T-DXd trial, “The benefit [with T-DXd] was huge, so we expected the FDA was likely to approve it based on the strength of the data, because it was designed, if the study was positive and the drug was safe, [for the indication to] get approval, which it did.”